Medartis Holding AG

BATS-CHIXE:MEDZ Stock Report

Market Cap: CHF 900.0m

Medartis Holding Valuation

Is MEDZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MEDZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 21.24
Fair Value
248.3% overvalued intrinsic discount
3
Number of Analysts

Below Fair Value: MEDZ (CHF74) is trading above our estimate of fair value (CHF21.24)

Significantly Below Fair Value: MEDZ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MEDZ?

Key metric: As MEDZ is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MEDZ. This is calculated by dividing MEDZ's market cap by their current revenue.
What is MEDZ's PS Ratio?
PS Ratio4x
SalesCHF 224.83m
Market CapCHF 900.02m

Price to Sales Ratio vs Peers

How does MEDZ's PS Ratio compare to its peers?

The above table shows the PS ratio for MEDZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.1x
NIOX NIOX Group
6.4x10.7%UK£266.9m
AOTI AOTI
1.9x21.4%UK£85.1m
SN. Smith & Nephew
2.1x4.9%UK£9.4b
EKF EKF Diagnostics Holdings
1.9x6.8%UK£96.5m
MEDZ Medartis Holding
4x12.3%CHF 900.0m

Price-To-Sales vs Peers: MEDZ is expensive based on its Price-To-Sales Ratio (4x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does MEDZ's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
SPEC INSPECS Group
0.2x4.3%US$56.84m
DEMG Deltex Medical Group
0.3xn/aUS$575.27k
No more companies available in this PS range
No. of Companies5PS01.63.24.86.48+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MEDZ is expensive based on its Price-To-Sales Ratio (4x) compared to the UK Medical Equipment industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is MEDZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MEDZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4x
Fair PS Ratio4.2x

Price-To-Sales vs Fair Ratio: MEDZ is good value based on its Price-To-Sales Ratio (4x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MEDZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 74.00
CHF 91.13
+23.2%
4.1%CHF 95.00CHF 86.00n/a3
May ’26CHF 77.00
CHF 91.13
+18.4%
4.1%CHF 95.00CHF 86.00n/a3
Apr ’26CHF 73.10
CHF 91.13
+24.7%
4.1%CHF 95.00CHF 86.00n/a3
Mar ’26CHF 73.50
CHF 91.13
+24.0%
4.1%CHF 95.00CHF 86.00n/a3
Feb ’26CHF 67.70
CHF 102.47
+51.4%
7.2%CHF 110.00CHF 92.40n/a3
Jan ’26CHF 56.60
CHF 102.47
+81.0%
7.2%CHF 110.00CHF 92.40n/a3
Dec ’25CHF 56.00
CHF 102.47
+83.0%
7.2%CHF 110.00CHF 92.40n/a3
Nov ’25CHF 58.50
CHF 98.20
+67.9%
10.0%CHF 110.00CHF 85.40n/a4
Oct ’25CHF 56.50
CHF 98.20
+73.8%
10.0%CHF 110.00CHF 85.40n/a4
Sep ’25CHF 63.80
CHF 98.20
+53.9%
10.0%CHF 110.00CHF 85.40n/a4
Aug ’25CHF 72.70
CHF 98.98
+36.1%
9.5%CHF 110.00CHF 85.40n/a4
Jul ’25CHF 68.50
CHF 98.98
+44.5%
9.5%CHF 110.00CHF 85.40n/a4
Jun ’25CHF 75.80
CHF 98.98
+30.6%
9.5%CHF 110.00CHF 85.40n/a4
May ’25CHF 80.80
CHF 98.98
+22.5%
9.5%CHF 110.00CHF 85.40CHF 77.004
Apr ’25CHF 90.00
CHF 98.85
+9.8%
9.7%CHF 110.00CHF 84.90CHF 73.104
Mar ’25CHF 73.50
CHF 96.78
+31.7%
11.7%CHF 110.00CHF 81.80CHF 73.504
Feb ’25CHF 73.80
CHF 101.77
+37.9%
8.2%CHF 110.00CHF 90.30CHF 67.703
Jan ’25CHF 83.20
CHF 101.77
+22.3%
8.2%CHF 110.00CHF 90.30CHF 56.603
Dec ’24CHF 73.20
CHF 101.77
+39.0%
8.2%CHF 110.00CHF 90.30CHF 56.003
Nov ’24CHF 71.50
CHF 101.77
+42.3%
8.2%CHF 110.00CHF 90.30CHF 58.503
Oct ’24CHF 84.40
CHF 132.65
+57.2%
31.9%CHF 175.00CHF 90.30CHF 56.502
Sep ’24CHF 87.30
CHF 113.43
+29.9%
38.8%CHF 175.00CHF 75.00CHF 63.803
Aug ’24CHF 81.20
CHF 110.13
+35.6%
43.0%CHF 175.00CHF 63.00CHF 72.703
Jul ’24CHF 76.55
CHF 110.13
+43.9%
43.0%CHF 175.00CHF 63.00CHF 68.503
Jun ’24CHF 74.50
CHF 119.00
+59.7%
47.1%CHF 175.00CHF 63.00CHF 75.802
May ’24CHF 74.80
CHF 119.00
+59.1%
47.1%CHF 175.00CHF 63.00CHF 80.802
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
CHF 92.89
Fair Value
20.3% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 15:43
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medartis Holding AG is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric Le BerrigaudBryan Garnier & Co
Maria Vara FernándezBryan Garnier & Co
Hugo SolvetBryan Garnier & Co